Effects of Therapeutic and supra-therapeutic intravenous doses of mavoglurant (AFQ056) on the QTc interval in healthy subjects.

Trial Profile

Effects of Therapeutic and supra-therapeutic intravenous doses of mavoglurant (AFQ056) on the QTc interval in healthy subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2013

At a glance

  • Drugs Mavoglurant (Primary) ; Moxifloxacin
  • Indications Anxiety disorders; Chorea; Drug-induced dyskinesia; Fragile X syndrome; Gastro-oesophageal reflux; Parkinson's disease; Smoking withdrawal
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Sep 2013 New trial record
    • 31 Aug 2013 Results presented at the 11th Congress of the European Association for Clinical Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top